Barry Noel Harrington

Title: Barry Noel Harrington: Innovator in Peptide Technology

Introduction

Barry Noel Harrington is a notable inventor based in Dublin, Ireland. He has made significant contributions to the field of peptide technology, particularly in the area of immunology. His work focuses on developing innovative solutions that can impact health and disease management.

Latest Patents

Harrington holds a patent for a peptide derived from the Vaccinia virus protein A46. This peptide is designed to inhibit Toll-like receptor 4 (TLR4) signaling. The patent details a specific amino acid sequence that includes SEQ ID NO. 4, SEQ ID NO. 55, SEQ ID NO. 68, SEQ ID NO. 69, SEQ ID NO. 70, SEQ ID NO. 71, SEQ ID NO. 72, SEQ ID NO. 79, SEQ ID NO. 82, SEQ ID NO. 85, SEQ ID NO. 88, SEQ ID NO. 91, SEQ ID NO. 94, SEQ ID NO. 97, SEQ ID NO. 100, SEQ ID NO. 103, SEQ ID NO. 106, SEQ ID NO. 109, SEQ ID NO. 112, or SEQ ID NO. 115. The peptide may also include a delivery sequence, such as a cationic peptide, enhancing its effectiveness.

Career Highlights

Harrington is affiliated with Trinity College Dublin, where he engages in research and development in the field of biotechnology. His work has led to advancements in understanding how peptides can modulate immune responses, showcasing his commitment to scientific innovation.

Collaborations

Throughout his career, Harrington has collaborated with esteemed colleagues, including Tatyana Sergeevna Lysakova and Andrew Graham Bowie. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise.

Conclusion

Barry Noel Harrington is a distinguished inventor whose work in peptide technology has the potential to influence the future of immunology. His innovative approach and dedication to research continue to pave the way for advancements in health science.